Scarica l'app Stockscreener
11.01
1.70%
-0.19
Dopo l'orario di chiusura:
11.01
Precedente Chiudi:
$11.20
Aprire:
$11.22
Volume 24 ore:
984.18K
Relative Volume:
0.66
Capitalizzazione di mercato:
$1.41B
Reddito:
-
Utile/perdita netta:
$-45.86M
Rapporto P/E:
-29.65
EPS:
-0.3713
Flusso di cassa netto:
$-44.02M
1 W Prestazione:
-17.22%
1M Prestazione:
+5.87%
6M Prestazione:
+33.45%
1 anno Prestazione:
+75.04%
Intervallo 1D:
$10.86
$11.42
Intervallo di 1 settimana:
$10.79
$13.29
Portata 52W:
$4.85
$14.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Nome
Trevi Therapeutics Inc
Settore
Industria
Telefono
203-304-2499
Indirizzo
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
11.01 | 1.41B | 0 | -45.86M | -44.02M | -0.3713 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-08-21 | Iniziato | Morgan Stanley | Overweight |
| 2025-07-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Reiterato | Needham | Buy |
| 2025-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-30 | Iniziato | Raymond James | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-12 | Iniziato | B. Riley Securities | Buy |
| 2022-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | BMO Capital Markets | Outperform |
| 2019-06-03 | Iniziato | Needham | Buy |
| 2019-06-03 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | Stifel | Buy |
Mostra tutto
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Trevi Therapeutics, Inc. $TRVI Stock Position Increased by Pivotal bioVenture Partners Investment Advisor LLC - MarketBeat
Rosalind Advisors Inc. Trims Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics chief Farrell Simon to address pre launch excellence at U.S. rare disease event - Traders Union
Trevi Therapeutics at Leerink Global: Strategic Cough Treatment Advances By Investing.com - Investing.com Canada
Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough Control (NASDAQ:TRVI) - Seeking Alpha
Zacks.com featured highlights include Trevi, Metalla Royalty & Streaming and Vermilion - The Globe and Mail
Zacks.com spotlighted features include Trevi, Metalla Royalty & Streaming, and Vermilion - Bitget
Q4 and year end 2025 earnings call announced, Trevi Therapeutics outlines - Traders Union
Trevi Therapeutics to detail 2025 results and business updates Mar. 17 - Stock Titan
Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday - MarketBeat
Oppenheimer Maintains Outperform on TRVI (March 09, 2026) - Meyka
Trevi Therapeutics (TRVI) Secures FDA Support for Advanced Clini - GuruFocus
Trevi Therapeutics Aligns With FDA on Phase 3 Cough Trials - TipRanks
Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March - The Globe and Mail
Trevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from D. Boral Capital - MarketBeat
TRVI: D. Boral Capital Maintains Buy Rating with $19 Target | TR - GuruFocus
Trevi Therapeutics stock gets Oppenheimer nod on Phase 3 plans By Investing.com - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 9.9%Here's What Happened - MarketBeat
Trevi Therapeutics (TRVI) Advances with Phase 3 Trials for Haduv - GuruFocus
HC Wainwright Reiterates Buy Rating for Trevi Therapeutics (TRVI) at $21 | TRVI Stock News - GuruFocus
Trevi Therapeutics' (TRVI) Buy Rating Reiterated at HC Wainwright - MarketBeat
TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns - Stocktwits
Trevi Therapeutics (TRVI) has successfully completed the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). - Bitget
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough - Bitget
Trevi Therapeutics Announces Completion of End-of-Phase 2 - GlobeNewswire
How supply chain issues affect Trevi Therapeutics Inc. stock2025 Year in Review & Technical Pattern Based Signals - Naître et grandir
Stock Recap: Can Trevi Therapeutics Inc continue delivering strong returnsWeekly Investment Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Earnings Recap: Is Trevi Therapeutics Inc stock technically oversoldQuarterly Profit Report & Accurate Buy Signal Alerts - baoquankhu1.vn
Inflation Data: Can Trevi Therapeutics Inc continue delivering strong returnsPortfolio Performance Report & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Can Trevi Therapeutics Inc continue delivering strong returnsQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn
Value Recap: Can Trevi Therapeutics Inc continue delivering strong returnsJuly 2025 Chart Watch & Advanced Technical Signal Analysis - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Trevi Therapeutics, Inc. Senior Management to Present at 2026 Healthcare Conferences - Quiver Quantitative
Chronic cough treatment talks: Trevi execs head to Miami and Philly in March - Stock Titan
MAI Capital Management Cuts Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Assessing Trevi Therapeutics (TRVI) Valuation After Strong Long Term Returns And A Rich Price To Book Ratio - Yahoo Finance
TRVI Should I Buy - Intellectia AI
TRVI PE Ratio & Valuation, Is TRVI Overvalued - Intellectia AI
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Promising 87% Potential Upside Captures Investor Attention - DirectorsTalk Interviews
TRVI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect? - Finviz
[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Trevi Therapeutics (TRVI) officer receives 35,000-share stock option grant - Stock Titan
Executive at Trevi (NASDAQ: TRVI) granted 160,000 stock options - Stock Titan
Trevi Therapeutics (TRVI) CSO awarded stock options on 85,000 shares - Stock Titan
Will Trevi Therapeutics Inc. outperform its industry peersJuly 2025 Volume & AI Driven Stock Price Forecasts - mfd.ru
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Trevi Therapeutics Executives to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Promising 99% Potential Upside In Biotech - DirectorsTalk Interviews
Can Trevi Therapeutics Inc. disrupt its industryDay Trade & Safe Investment Capital Preservation Plans - mfd.ru
Is Trevi Therapeutics Inc. stock resilient to inflationGold Moves & Fast Entry High Yield Stock Tips - mfd.ru
Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):